The invention relates to an organic polyspiralgrid nanopolymer material and a preparation method thereof, and belongs to the field of nanotechnology and organic electronics. The structure of the organic polyspiralgrid nanopolymer material is composed of grids containing a spiro ring that serves as a repeat unit to form a special nano polymer, and the structure shares the spiro ring structure. A synthetic method thereof relates to a synthon containing the spiro ring, and by means of a Friedel-Crafts reaction, an organic spirogrid and a nano polymer thereof are built. By means of reasonable molecular design and the Friedel-Crafts reaction with the advantages of being mild in reaction condition, high in yield, high in selectivity, simple in posttreatment, green, free of toxicity and the like, the problems that a traditional polymer molecule is complex in synthesis step, toxic in posttreatment, large in pollution and the like are solved.

The invention relates to an organic polyspiralgrid nanopolymer material and a preparation method thereof, and belongs to the field of nanotechnology and organic electronics. The structure of the organic polyspiralgrid nanopolymer material is composed of grids containing a spiro ring that serves as a repeat unit to form a special nano polymer, and the structure shares the spiro ring structure. A synthetic method thereof relates to a synthon containing the spiro ring, and by means of a Friedel-Crafts reaction, an organic spirogrid and a nano polymer thereof are built. By means of reasonable molecular design and the Friedel-Crafts reaction with the advantages of being mild in reaction condition, high in yield, high in selectivity, simple in posttreatment, green, free of toxicity and the like, the problems that a traditional polymer molecule is complex in synthesis step, toxic in posttreatment, large in pollution and the like are solved.

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1): ##STR00001##

The present invention discloses an organic compound represented by the following formula (1) and an organic electroluminescence device using the organic compound as the phosphorescent host material, the fluorescent host material, or the fluorescent dopant material. The organic compound may increase a current efficiency or half-life of the organic electroluminescence device. ##STR00001##

The present invention discloses an organic compound represented by the following formula (1) and an organic electroluminescence device using the organic compound as the phosphorescent host material, the fluorescent host material, or the fluorescent dopant material. The organic compound may increase a current efficiency or half-life of the organic electroluminescence device. ##STR00001##

Photoactive compounds are disclosed. The disclosed compounds can exhibit molecular structural elements tending to increase the evaporability of the compounds, such as by including geometric core disruption by use of conformationally restricted side groups instead of freely rotatable side groups or use of indandione moieties instead of dicyanomethyleneindanone moieties. The disclosed photoactive compounds include those with an imine-bridging linking moiety, which can shift the optical properties to a more red-shifted absorbance as compared to compounds with an alkene-bridging linking moiety. The disclosed photoactive compounds can be used in organic photovoltaic devices, such as visibly transparent or opaque photovoltaic devices.

Photoactive compounds are disclosed. The disclosed compounds can exhibit molecular structural elements tending to increase the evaporability of the compounds, such as by including geometric core disruption by use of conformationally restricted side groups instead of freely rotatable side groups or use of indandione moieties instead of dicyanomethyleneindanone moieties. The disclosed photoactive compounds include those with an imine-bridging linking moiety, which can shift the optical properties to a more red-shifted absorbance as compared to compounds with an alkene-bridging linking moiety. The disclosed photoactive compounds can be used in organic photovoltaic devices, such as visibly transparent or opaque photovoltaic devices.

Photoactive compounds are disclosed. The disclosed compounds can exhibit molecular structural elements tending to increase the evaporability of the compounds, such as by including geometric core disruption by use of conformationally restricted side groups instead of freely rotatable side groups or use of indandione moieties instead of dicyanomethyleneindanone moieties. The disclosed photoactive compounds include those with an imine-bridging linking moiety, which can shift the optical properties to a more red-shifted absorbance as compared to compounds with an alkene-bridging linking moiety. The disclosed photoactive compounds can be used in organic photovoltaic devices, such as visibly transparent or opaque photovoltaic devices.

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

##STR00001##

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

##STR00001##